Second medical use patents: outcome of the Pregabalin case

The assessment of the infringement of second medical use patents is an issue French and European courts have been interested in for several years. A series of recent decisions have resulted in a number of convergent points being outline more precisely as well as practical consequences for the stakeholders in the pharmaceutical industry. This study focuses ont the subject in France and, on a broader scale, in Europe.

For more information.